‘Am I really gonna go sixty years without getting cancer again?’ Uncertainty and liminality in young women’s accounts of living with a history of breast cancer by Rees, Sophie
  
 
 
 
warwick.ac.uk/lib-publications 
 
 
 
 
 
Manuscript version: Author’s Accepted Manuscript 
The version presented in WRAP is the author’s accepted manuscript and may differ from the 
published version or Version of Record. 
 
Persistent WRAP URL: 
http://wrap.warwick.ac.uk/96645                            
 
How to cite: 
Please refer to published version for the most recent bibliographic citation information.  
If a published version is known of, the repository item page linked to above, will contain 
details on accessing it. 
 
Copyright and reuse: 
The Warwick Research Archive Portal (WRAP) makes this work by researchers of the 
University of Warwick available open access under the following conditions.  
 
Copyright © and all moral rights to the version of the paper presented here belong to the 
individual author(s) and/or other copyright owners. To the extent reasonable and 
practicable the material made available in WRAP has been checked for eligibility before 
being made available. 
 
Copies of full items can be used for personal research or study, educational, or not-for-profit 
purposes without prior permission or charge. Provided that the authors, title and full 
bibliographic details are credited, a hyperlink and/or URL is given for the original metadata 
page and the content is not changed in any way. 
 
Publisher’s statement: 
Please refer to the repository item page, publisher’s statement section, for further 
information. 
 
For more information, please contact the WRAP Team at: wrap@warwick.ac.uk. 
 
‘Am I really gonna go sixty years without getting cancer again?’ Uncertainty and liminality in young 
women’s accounts of living with a history of breast cancer. 
Word Count: 7,979 
Author: Dr. Sophie Rees,University of Warwick 
Address: Warwick Medical School, Clinical Trials Unit, Gibbet Hill Campus, Coventry, CV4 7AL 
Contact number: (+44)2476523912 
Email: S.Rees.1@warwick.ac.uk 
 
Sophie Rees is a research fellow at the University of Warwick. She is a sociologist whose research 
interests include: illness experience; cancer; identity; risk and uncertainty; women’s health; gender; 
and qualitative methodologies. The findings in this article are from her doctoral research, completed 
in December 2015. She is currently based at Warwick Clinical Trials Unit – perhaps an uncommon 
habitat for a sociologist – where she is utilising qualitative methods to add depth and understanding to 
trial outcomes, and involving patients and carers in the design and conduct of trial research. 
  ‘Am I really gonna go sixty years without getting cancer again?’ Uncertainty and liminality in young 
women’s accounts of living with a history of breast cancer. 
Abstract  
Although much research has examined the experience of breast cancer, the distinctive perspectives 
and lives of young women have been relatively neglected. Women diagnosed with breast cancer under 
the age of 45, and who had completed their initial treatment, were interviewed, and social 
constructionist grounded theory methods were used to analyse the data. The end of initial treatment 
was accompanied by a sense of unease and uncertainty in relation to recurrence and survival, and also 
fertility and menopausal status. The young women’s perceptions about the future were altered, and 
their fears about recurrence were magnified by the possibility of many decades ahead during which 
breast cancer could recur. The implications for the young women’s life course, in terms of whether 
they would be able to have children, would not become clear for several years after initial treatment. 
This resulted in a liminal state, in which young women found themselves neither cancer-free nor 
cancer patients, neither pre- nor post-menopausal, neither definitively fertile nor infertile. This liminal 
state had a profound impact on young women’s identities and sense of agency. This extends previous 
understanding of life after cancer, exploring the age-related dimensions of liminality. 
Introduction 
The experience of receiving cancer treatment, and subsequently living long-term with a history of 
cancer, is becoming more and more common. Breast cancer is the most common cancer in the UK, 
and the survival rate is one of the highest, with around 8 in 10 women living beyond ten years. This 
means that there exists a large population of women living with a history of breast cancer. Interest in 
women’s experiences of breast cancer has grown since the 1980s, alongside the increase in research 
about the experience of illness in the field of the sociology of health and illness [1]. Yet, the 
experience of being a young woman living with a history of breast cancer remains relatively 
underexplored, particularly in the UK. Around 80% of breast cancers in the UK are diagnosed in 
women over 50 [2], but the numbers of younger women diagnosed each year have been steadily 
increasing in the UK, and in Europe as a whole [3, 4], and it is the most commonly diagnosed form of 
cancer in women aged 18-39 in the UK. Thomas-MacLean [5] argued that “the ramifications of breast 
cancer and its treatments affect all spheres of life, including appearance, family relationships, moral 
dilemmas, and interactions with medical professionals” (p.638), and the impact continues long after 
the end of treatment. A recent report from Macmillan Cancer Support [6] highlighted the long-term 
consequences of cancer and argued that “we have to recognise that ‘not dying’ [from cancer] is not 
the same as ‘being well’”. 
This study aimed to explore the experiences and perceptions of young women living with a history of 
breast cancer in the UK. This paper focuses on the impact of breast cancer on a young woman’s life 
course and identity. Specifically, it explores the effect of the uncertainty engendered by the diagnosis 
and treatment of breast cancer at a young age, and the evidence for resulting liminality in the young 
women’s accounts. 
Liminality 
The concept of liminality [7] emerged through the literature review as potentially relevant to 
understanding the experiences and perceptions of young women living with a history of breast cancer. 
Liminality as a concept first originated in anthropological studies of rites of passage [8, 9]. Such rites 
of passage were observed to begin with a severing of the connection with a previous social position, 
followed by an ambiguous stage, before the individual re-enters society with a new identity and 
occupies a different position in the social structure [10, 11]. The ‘liminal’ state is the middle stage, 
characterised by uncertainty and in which the person is situated “betwixt and between fixed social 
positions” [10].  
Although the concept emerged from anthropological studies, it has been used in recent decades to 
describe the experience of living with a history of cancer. Little et al. [7] argued that a person who has 
had cancer enters into a state of liminality in which he or she is classified as neither ill nor well. Little 
et al.’s formulation differs from the earlier anthropological work because they did not conceptualise it 
as three separate stages, but as a process; “an enduring and variable state” [7]. Little et al.’s 
formulation echoes Sontag [12], who argued that people who have had cancer belong fully to neither 
the “kingdom of the well [or the] kingdom of the sick”, as well as Frank’s [13] description of the 
‘remission society’. There were three themes in the accounts of people with a history of colorectal 
cancer which Little et al. identified as constituting liminality: ‘cancer patientness’; ‘communicative 
alienation’; and ‘boundedness’ (p.1486). ‘Cancer patientness’ referred to the way that, regardless of 
length of time since treatment,  respondents continued to speak from the position of a cancer patient 
and described the ways that everyday life was irreversibly changed, with cancer occupying their 
thoughts most days. Interviewees talked about a sense of alienation and separation they felt from 
those who had not had cancer, and the authors named this ‘communicative alienation’. ‘Boundedness’ 
referred to the experience of feeling restricted in terms of time and space (such as staying in hospital 
during recovery from surgery), and the surrendering of social and working roles. Participants felt a 
sense of uncertainty about the future and limitations in the freedom to move through space, 
particularly because of the physical constraints which having a stoma bag entailed in terms of 
requiring access to bathrooms.  
Drawing on Little et al. (1998), a small number of studies have used the concept of liminality in 
research about living  with a history of breast cancer [14], prostate cancer [15, 16], and various types 
of cancer [17]. Hubbard and Forbat (2012) found that participants perceived cancer as a continuing 
threat regardless of the time since diagnosis or the presence of long-term physical effects of treatment, 
and also that cancer was referred to as an ongoing threat in terms of recurrence more amongst 
participants diagnosed under the age of 50, although they did not explore why this might have been. 
In Navon and Morag’s [15] study, men reported that treatment left them feeling simultaneously 
‘better’ and ‘worse’ because, while the symptoms of prostate cancer had been remedied, they 
experienced other losses in terms of libido and impotence. Cayless et al. [16] expanded on this work, 
finding that the language used by the men in their study often suggested that they were caught 
between fear of recurrence and hope of change, illustrating liminality.  The current study builds upon 
this literature, contributing the stories of young women with a history of breast cancer, and looking at 
the significance of age in the experience of liminality after cancer. Little et al.’s conception of 
liminality will be drawn on in exploring the young women’s accounts. 
Fertility 
An important aspect of living with a history of breast cancer as a young woman is the impact of 
treatment on fertility and menopausal status. Treatment for breast cancer, such as chemotherapy and 
Tamoxifen, can leave women with low or no ovarian function, and can cause young women to enter a 
premature menopause. Pregnancy rates for women beyond breast cancer have been shown to be 70% 
lower than in the general population [18]. Most women experience menopausal symptoms after breast 
cancer, and healthcare providers are often unable to tell women whether their menopause is temporary 
or permanent [19].Concerns related to fertility have been found to be amongst the biggest concerns 
for young women living beyond breast cancer [20-22], and there have been recent calls for more 
research about the subjective experience of fertility and infertility after cancer [23, 24]. Researchers in 
this area have identified the significance of  the uncertainty about fertility [23-25]. Findings from this 
body of research have echoed Little et al.’s themes of liminality. Halliday et al. [25] argued that 
women living with uncertainty about their fertility after treatment for haematological cancer felt 
profoundly different to and disconnected from their peers, reminiscent of Little et al.’s (1998) 
description of ‘communicative alienation’, as the women found it difficult to cope with the 
uncertainty of whether they would be able to go through the same experiences of having children as 
their friends and family. Halliday et al. also argued that the women in their study experienced a 
heightened awareness of the constraints of time, and a loss of the taken-for-granted assumptions that 
they would be able to have children, and that they had plenty of time in which to do so, similar to 
Little et al.’s ‘boundedness’. This was exacerbated by uncertainty such as about how long it would 
take to become pregnant, and whether they would need IVF treatment.  
These findings indicate that the concept of liminality may have potential in understanding this 
experience and young women’s perceptions of uncertain fertility after breast cancer. This study 
expands on this work, making the link between uncertain fertility and liminality after cancer. Previous 
research exploring breast cancer and liminality [14] has not considered the distinctive experiences of 
younger women such as those related to fertility, and how this might be understood in terms of 
liminality. While women living with a history of breast cancer may not currently have cancer, their 
history of cancer engenders uncertainty about the future in terms of recurrence, and also related to 
fertility. The concept of liminality facilitates insight into those whose experiences blur the boundaries 
between ill and healthy. 
The new normal 
There is a concept emerging in research and writing about cancer experience: that of the ‘new normal’ 
[14, 26-28]. In the oncologist Mukherjee’s [26] book, a woman undergoing treatment states that, “for 
someone who is sick, this is their new normal” (p.449) [original emphasis]. She was referring to her 
everyday life which had become structured by treatment. Other research has described constructing a 
‘new normal’ as a way of rebuilding one’s identity and accepting that everyday life will never be quite 
the same [27, 28]. Trusson approached her recent research with the question ‘what does the new 
normal look like for women living beyond breast cancer treatment?’, thus assuming that there is a new 
normal after the end of treatment [14]. Indeed, Trusson’s participants did not seem to be striving 
towards a return to normal, instead facing and sometimes embracing a new, altered identity. This 
study aimed to explore whether younger women living with a history of breast cancer were living 
with a new normal, given the uncertainty regarding fertility and menopausal status. 
Existing research has looked at women’s concerns about uncertain fertility after breast cancer for 
younger women, and in this paper I bring uncertainty and liminality together to show that uncertainty 
about fertility (and also menopause) shape a young woman’s identity and sense of agency after breast 
cancer, as she finds herself between identities.  
Methods 
This exploratory research was situated within the interpretive paradigm, a perspective which assumes 
that, in order to understand a social phenomenon, researchers must explore it from the perspectives of 
individuals experiencing it [29-32]. The aim was to understand the experience and meaning of being a 
young woman with a history of breast cancer from the perspectives of the young women themselves. 
To achieve this aim, the study’s methodology was informed by social constructionist grounded theory  
[30, 33], as grounded theory methods aim to produce an understanding of a social phenomenon which 
is led by the data, grounded in the accounts of those experiencing it, and, therefore, resonates with 
their experience and makes sense to them[34-36]. Although the original formulation of grounded 
theory, the “discovery of theory from data” [34], has been criticised (including by feminist 
scholars[37]) for remaining within a positivist paradigm, Charmaz aimed to develop a grounded 
theory method better suited to the interpretivist paradigm, and a social constructionist theoretical 
position. I therefore utilised the “systematic, yet flexible, guidelines” [33] offered by this method, 
which enabled a close and in-depth analysis of the data. Key feminist methodological and ethical 
principles were also integral to the research methodology. Feminist research aims to develop 
knowledge which is reflective of women’s own voices [38, 39], and positions women’s subjective 
meanings as central to understanding their experiences. It also seeks to understand the influence of 
social structure and culture on women’s experiences and perceptions. Feminism and social 
constructionist grounded theory are complementary as both approaches position participants as central 
to the research, and their experiences as a legitimate source of knowledge [40]. It has also been argued 
that grounded theorists can learn much from feminist practices of reflexivity [37]. 
Research design 
Participants were accessed through a diverse group of gatekeeper organisations and support groups. 
The inclusion criteria for the study, developed from the literature review, were: 
- Woman diagnosed with breast cancer while aged between 18-44 
- Diagnosed at least twelve months previously, and within the last ten years 
- Completed initial treatment in the UK 
- Not currently receiving treatment for cancer, other than long-term preventative treatment such 
as Tamoxifen 
The age range was chosen because the age of 44 is well below 50, which is the age over which the 
majority (80%) of breast cancers are diagnosed. It is also well below the average age (50-51) of 
menopause, increasing the likelihood of reaching a group of women who were pre-menopausal at 
diagnosis, an issue which the literature review indicated was significant. Twenty women took part in 
qualitative, semi-structured interviews, and a further three women who met the inclusion criteria 
participated in three stakeholder panel meetings throughout the course of the research, in order to 
engage women in the research. Semi-structured interviews gave women a level of freedom to choose 
how to tell their stories, consistent with feminist research methods, but also enabled me to provide 
prompts and to further investigate areas identified as important through the literature review and 
preliminary analysis, consistent with grounded theory methods.  
The data analysis was informed by Charmaz’s (2006) guidelines for grounded theory methods of 
analysis, and involved three phases of coding data. Coding refers to “categorising segments of data 
with a short name that simultaneously summarises and accounts for each piece of data” [33]. 
Preliminary analysis in the form of initial coding was conducted concurrently with data collection. 
Initial coding was conducted with the aim of summarising each segment in terms of processes, rather 
than applying pre-existing theoretical categories to it. Some segments were coded in the women’s 
own words which enabled their understandings and perceptions to remain intact. After the initial 
phase, I conducted focused coding. This involved sorting and synthesising initial codes, and making 
decisions about which codes were the most useful, significant, and effective, in building an 
interpretation of the data. Finally, I focused the analysis by drawing on each element of the theoretical 
framework in turn, in order to explore in depth the women’s accounts in relation to each research 
question.  
Reflexivity, a critical reflection upon how the position, background, knowledge of the researcher 
shaped the research, is regarded by many as an essential aspect of qualitative research [41], especially 
feminist research [38, 39, 42]. Given that a feminist methodology positions women’s knowledge as 
arising from their subjective experience, the researcher must also be viewed in the same way. There 
were undoubtedly ways that my social position as a white, able-bodied, heterosexual, young woman 
studying at a university, shaped how I was perceived by participants, and the conversation in the 
interviews. An important difference between myself and the interviewees was that I had not had 
breast cancer, and this inevitably impacted on the interviews. For example, some women may have 
wanted to protect me from the most distressing parts of their story. On the other hand, many women 
used the opportunity to confide in me their fears and other distressing emotions. As a young woman 
myself, I became acutely aware that the women’s stories were also potentially my story. I remember 
sensing this particularly when interviewing Naomi because when Naomi was diagnosed, she was the 
same age as I was at the time of the interview, a fact of which we were both aware during the 
interview, as she had asked me my age before we began.  
Ethical considerations were crucial when designing the study, and the research was approved by the 
Humanities and Social Sciences Research Ethics Committee at the University of Warwick. 
Researching sensitive subjects such as the experience of a serious illness and its effects on a woman’s 
perceptions of her body and identity, raises the potential for causing distress, and the interviews were 
carried out with the greatest care to remain sensitive and respectful towards the interviewees. Consent 
was understood as a process [43] negotiated throughout the research, with participants being informed 
that they were not obliged to take part, nor answer every question, and reminded that they could 
withdraw at any point, including after the interview. Throughout the interviews, I made sure women 
understood that they were under no obligation to answer any questions, or speak about any topics 
which they felt were too private or which they did not feel comfortable speaking about. I also spoke 
with them about the aim and purpose of the research, and informed them about how their accounts 
would be treated. I made sure that they felt comfortable with their voice being recorded and 
transcribed, and assigned them a pseudonym, removing any potentially identifiable information.  
The interviewees 
The young women who took part in the study ranged in age from 26 to 53, and were aged 22-43 at 
diagnosis. The time since diagnosis ranged from 15 months to nine years, with an average of 3.5 
years. Table 1 provides more demographic and treatment information about the participants. Most of 
the women (17) were married, civil partnered, or cohabiting, two were in relationships and one was 
single. Three women interviewed were pregnant when they were diagnosed, all with their first, and at 
the time of the interview, only, child. All women had completed their initial treatment, receiving a 
combination of the most common forms of breast cancer treatment: surgery, chemotherapy, and 
radiotherapy. All women were interviewed after their first diagnosis of breast cancer, with the 
exception of one woman, who had been treated twice after it was discovered to have spread one year 
after her first diagnosis. Nineteen of the women received long-term preventative treatment such as 
Tamoxifen, Zoladex, or Herceptin. Fifteen women received chemotherapy, and nineteen underwent 
radiotherapy.  
Characteristic Number (Percentage of sample) Range (Mean) 
Age at diagnosis  
18-24 
 
1 (5) 
22-44 (33.8) 
26-30 6 (30)  
31-35 4 (20)  
36-40 4 (20)  
41-44 5 (25)  
Age at interview - 26-53 (37) 
Time since diagnosis - 15 months–9 years (3.5 years) 
Ethnicity 
White 
 
17 (85) 
 
 
Asian 1 (5)  
Black 1 (5)  
Dual heritage 1 (5)  
Sexual identity 
Undisclosed 
 
18 (90) 
 
 
Lesbian 2 (10)  
Disability (before 
diagnosis) 
None 
 
18 (90) 
 
Yes 2 (10)  
Findings 
Uncertainty emerged as a significant theme in the women’s accounts of their lives after treatment. The 
young women faced uncertainty about two areas: the possibility of recurrence and their status as 
survivors; and fertility and the future of their life course. The young women’s assumptions about their 
lives were challenged during the diagnosis and initial treatment stage, but the implications for the rest 
of their lives were as yet uncertain, and this was something which the women described as having to 
face from the end of curative treatment.  
Uncertainty about recurrence and cancer-free status 
The young women experienced profound uncertainty surrounding the question of whether their 
treatment had been successful, and whether they would experience a cancer recurrence. The treatment 
ended, it seemed, abruptly, and women had expected to feel positive and well, especially at the end of 
chemotherapy. Instead, they found that they felt emotionally and existentially vulnerable, reflecting 
on the enormity of the experience of having gone through cancer treatment and its implications for 
their future. The fear of recurrence has been noted in other studies about the experience of breast 
cancer from the perspectives of women of all ages [44-46]. The young women in this study felt that it 
was particularly difficult for them to face their mortality and the possibility of a foreshortened life 
span at their age. They considered the risk of recurrence and its implications for them as younger 
women. 
‘If you get cancer when you’re 60 and you look at it that you may get it in ten years’ time 
you’re at a fairly good age, whereas if I get it back when I’m 40, which might not happen but 
there’s still a huge chance that it will, I’m still like super young really at 40.’ – Lyndsey, 31 at 
diagnosis 
‘Because I was like 22 when I was diagnosed I think, y’know, “What’s a nice age to live to? I 
guess like 82” and I kind of always said to myself “Am I really gonna go sixty years without 
getting cancer again?”’ – Faith, 22 at diagnosis  
These accounts demonstrate poignantly the significance of age to young women’s lives after breast 
cancer, and having to live for such a long time with the burden of this uncertainty.  
The women felt heavily reliant on medical knowledge to define them as being healthy or ill, as having 
cancer or not, yet, after the end of initial treatment, the young women were confronted with the 
realisation that medical knowledge was limited in its ability to define them as cancer-free.  
‘No one scans you and says “You’re alright now”, they just say “We think the treatment 
we’ve given you should kill any cells that are possibly stray”.’ – Lyndsey, 31 at diagnosis 
“It’s not spread as far as I know, at the moment they say it’s nothing – ‘No evidence detected’ 
they say at the minute.” – Beverley, 36 at diagnosis 
As a result, the young women found that they could not perceive themselves as cancer-free. The 
language many of them used showed that they perceived cancer to be lurking within their bodies.  
 ‘For all I know my cancer could still be there, like a tiny little cell that one day will explode.’ 
– Melanie, 27 at diagnosis  
‘There’s an element in my head of worrying if it’s still there lurking.’ – Dawn, 27 at diagnosis 
Exacerbating this, was the sense that others around them assumed that they were now ‘well’, but this 
was contrary to how they felt. 
‘Everybody thinks I’m back to normal it’s kind of like “Oh you’re fine now, you beat it”. I 
haven’t beat it I’m still, not even in remission they don’t even call it that it’s kind of like I’m 
still trying to prevent it from coming back…And you kind of want to shake people and go 
“I’m not okay, just listen to me!”’ – Gemma, 33 at diagnosis 
Gemma’s account in indicative of Little et al.’s (1998) theme of ‘cancer patientness’. The young 
women could not easily see themselves as cancer-free, and cancer was experienced and perceived as 
an ongoing presence in their thoughts, and even in their bodies. Rather than being categorised as 
either ill or well, the young women found themselves in a space ‘betwixt and between’ healthy and ill 
[47]. Participants also described hiding their ongoing fears about recurrence from people around them, 
and feeling unable to express the reality of their experience to others because of the assumption that 
they were now returned to normal. This can be understood as ‘communicative alienation’ (Little et al. 
1998), a facet of being in a liminal state. 
Uncertainty about fertility  
A further dimension of uncertainty which the young women experienced was surrounding fertility and 
menopausal status, and this was a significant theme in many of the interviews. The impact of breast 
cancer treatment on an individual woman’s fertility is difficult for health professionals to determine. 
Reproduction and fertility have been identified in previous studies as among the most important 
concerns of younger women living with a history of breast cancer [20, 44, 46], but here I highlight the 
importance of the uncertainty about fertility and the way that this can be understood as a liminal state 
for the young women. 
Thirteen of the participants told me that at the time of their diagnoses either that they had been 
planning on having (more) children, or that they were undecided but had not ruled it out. Many of the 
women interviewed were therefore hoping that the menopausal symptoms they were experiencing 
were temporary, their menstrual cycle would return to normal once they finished hormonal treatment, 
and that they would then be able to conceive.  
‘I’ll find out in the next few years whether I can [have children] or not, assuming I’m in the 
position to start.’ – Faith, 22 at diagnosis  
Even those women who were no longer receiving long-term hormonal treatment, and had been told by 
their doctors that their fertility was normal, were still experiencing profound uncertainty. 
 ‘I asked my oncologist to give me a fertility test and he’s like ‘Yep you’re fertile’. But I 
know I will never know until I, fingers crossed, try to have children.’ – Melanie, 27 at 
diagnosis  
For Naomi, becoming pregnant was a major goal and would be the point at which she would feel 
recovered from the cancer. 
‘We’ve got two years left of Tamoxifen…And then we’ll start trying for a baby. Which is the 
ultimate goal now, after, and that will be my “That’s it, put it behind me”. That’s always been 
like my end to it all. So I’ll be living it now until that moment where I can say “I’m 
pregnant”. And then I’m gonna put it behind me as much as I can.’ – Naomi, 26 at diagnosis 
The uncertainty which arose with regards to fertility can be understood as a suspended state in which 
the women were unable to categorise themselves as either fertile or not, able to have children or not, 
and many of the young women were waiting to not only move on to the next phase of their lives, but 
waiting to see what would be possible within the next phase. 
All but four of the women were still on long-term hormonal treatment at the time of interview, such as 
Tamoxifen, which inhibits the amount of oestrogen absorbed by cells in the body in order to prevent 
recurrence. The length of this preventative treatment, and therefore the length of their treatment-
induced menopause, was largely unclear for the young women, adding yet another layer or 
uncertainty.  
‘[It would] just be nice if they say after five years: “That’s it we can stop it”.’ – Gemma, 33 at 
diagnosis  
Some of the participants were told when they began treatment that they would be able to come off 
Tamoxifen after two or three years in order to have a child and then go back on it to complete the 
five-year recommended course. However, this was something which the women were unsure would 
actually happen. 
 ‘I need to be on it [hormone treatment] for minimum five in total but he has said that after 
two years I can maybe have a break to have a child.’ – Hayley, 29 at diagnosis 
‘After three years of taking it, if it’s all clear and we’re happy, we could think about coming 
off it to try and have children…We just have to see how it goes.’ – Evelyn, 33 at diagnosis  
It seemed that, for some women, if they did not experience a recurrence within the first two or three 
years they might be able to take a break from their hormonal treatment in order to have children. 
Uncertainty about recurrence and fertility were, therefore, interlinked. Little et al. (1998) argued that 
their participants continued to speak from the position of ‘cancer patient’, regardless of the time since 
their treatment. It is clear that although the women in this study did not have cancer, and were not 
cancer ‘patients’, neither did they feel that they had fully moved on to being ‘well’. A few of the 
women had tried to negotiate taking this break from their Tamoxifen regime in order to conceive. 
However, this was less straightforward that they had hoped, and they had found their doctors resistant 
to the idea.  
‘I went in and I said ‘I want to finish’ and he said “No”. I said “I’d like to start having kids” 
and…He looked at me and said “Naomi if you stop your Tamoxifen now and have a baby you 
won’t be here to look after it”.’ – Naomi, 26 at diagnosis  
Diagnosed at the age of 26, Naomi expressed her sense of injustice at, and frustration with, this loss of 
control. She described the above exchange as ‘Like a 60-year-old man is controlling my life’. With 
their life course disrupted and constrained by the treatment timescale, the young women had to 
balance their wishes to have children, with the importance of preventing recurrence.  
‘I just can’t wait until it’s over, I just can’t wait. It’s like a pause on my life.’ – Naomi, 26 at 
diagnosis   
This highlights important distinctive aspects of young women’s experiences of living with a history of 
breast cancer: that of uncertainty regarding fertility; the length of time of such uncertainty; and the 
implications of breast cancer on their life course. Waiting until the end of long-term treatment, or until 
their oncologists agreed that they could take a break, to find out if they could conceive, was 
experienced as a liminal state. Uncertainties and fears about recurrence and fertility therefore 
interweaved to produce an uncertain future for the young women.  
The treatment for breast cancer for a young woman, can last over six years when surgery, 
chemotherapy, radiotherapy, and hormonal preventative treatment are taken into account. This had 
particular implications for the some of the young women who were at a certain stage in their life, as it 
meant that the following six years from diagnosis would be dramatically different to the way the 
women had planned or anticipated them to be, displacing their major life plans.  
 ‘My Mum had an early menopause at 40, 41, and I knew…I would have to have Tamoxifen 
for five years and that I wasn’t allowed to get pregnant in that space of time…I knew then 
that I’d be 38, 39 coming out of it and that I’d have only a tiny little window, potentially a 
tiny window to get pregnant.’ – Evelyn, 33 at diagnosis  
Evelyn’s account illustrates the importance of timing. For Evelyn, the years on Tamoxifen stretched 
out ahead of her, and the time between the end of treatment and her anticipated early menopause was 
too short, restricting her chances of having children. The end of hormonal treatment does not 
immediately signify the point at which women might be able to conceive; the drug takes time to leave 
a woman’s system, and women are advised not to try to become pregnant for twelve weeks (Hickey et 
al. 2009). 
Like participants in another study [48], the women often held perceptions about the ideal time to have 
children, and breast cancer treatment left this temporal trajectory in disarray. 
‘I was kind of hoping that I’d have a child by at least 35, one, um, and we want to have a 
couple, so at least by the time I was 40 I was thinking we’d have two children. Um, and that’s 
just not gonna happen now.’ – Evelyn, 33 at diagnosis  
Many of the young women felt that they were deviating from a ‘normal’ life course, as well as their 
personal anticipated life trajectory, often comparing themselves to other women their age. 
‘All my friends and everyone around me is on one path and I’m kind of going, poodling on 
another.’ – Naomi, 26 at diagnosis  
Naomi’s use of ‘poodling’ indicates that she viewed the time on Tamoxifen to some extent to be 
wasted time, illustrating her experience and perception of a suspended state. Melanie described the 
sense of urgency which she felt to meet a partner and complete certain goals before she experienced a 
recurrence: 
‘Yeah deep down I think to myself “God I need to meet someone quickly and have them fall 
in love with me” because God forbid it comes back.’ – Melanie, 27 at diagnosis  
Existing research has noted that women with breast cancer experience a loss of control over their 
bodies and lives (Dunn and Steginga 2000; Thomas-MacLean 2004; Trusson 2013). Halliday et al. 
(2014) also found that loss of control was a strong theme in their study about the experiences of 
women who were uncertain about their fertility after haematological cancer treatment. In Little et al.’s 
conceptualisation of liminality, a theme was ‘boundedness’. The findings here highlight that young 
women with breast cancer experienced a loss of control which was related to their age at diagnosis 
and the implications of treatment for their life course. The women in the present study felt a loss of 
agency over their lives, bound by new rules of time. 
Not all of the young women were hoping to become mothers, and some of them had already had all 
the children they were planning to. Seven of the women were not, at the point of diagnosis, planning 
on having any (more) children. It is important not to neglect these women’s accounts, or to imply that 
all young women wish to have children. However, concerns about menopause and fertility did not 
necessarily relate to a desire for children, and an uncertain menopausal status had an impact on 
women’s identities regardless of whether they wanted children. None of the women interviewed had 
experienced menopausal symptoms before their treatment.  
For the women who were not planning on having children after treatment ended, uncertainty and 
liminality still characterised their experiences because they were unsure if they would return to a pre-
menopausal state after treatment.  
‘Once the injections are finished they don’t know whether my periods will restart, they can’t 
tell me that.’ – Beverley  
Some of the women were hoping their periods would resume and their menopausal symptoms would 
subside until they became naturally menopausal later in life. Others were hoping that the treatment-
induced menopause was permanent.  
‘They’re testing me at the moment just to see if I’ve actually gone into full menopause, um 
which I don’t mind if I have, but it would answer a lot of questions…I would stop worrying 
about it so much “Oh is it the drugs and if I stop taking them will all these things suddenly 
come back with a vengeance?”.’ – Sarah, 41 at diagnosis  
This builds on previous work on liminality, providing evidence that the young women found 
themselves between two positions: neither menopausal nor pre-menopausal. 
A new normal? 
It could be argued that some women find it useful to frame their lives living with the uncertainty 
engendered by cancer as ‘normality’, as Trusson did. People with a history of cancer know that they 
are unlikely to ‘return’ to a previous normality, so they need to construct a new normal. Indeed, one 
woman in my study used the term ‘new normal’ unprompted: 
‘It’s normal for me to wake up feeling about 80, like if I got up now I would probably hobble 
for a little bit but be fine and it’s just a new normal for me.’ – Beverley, 36 at diagnosis 
However, I think most of the accounts of the young women in this study raised a question about how 
relevant this concept is to understanding their experiences and perceptions. The uncertainties which 
arose from their experience of cancer, and the constraints placed on their lives as a result of the 
treatment, suggest that the women were in a state of liminality, waiting to find out what the 
implications for their lives would be, and if cancer would return before they were able to reach their 
life goals. 
‘At work sometimes I do walk along my corridor if I’ve had a good day and I just think “This 
is great I’m okay”, and I do have that fear, I definitely do, that I need to hurry up with things, 
I want to sort out my life like just in case I get ill again.’ – Melanie, 27 at diagnosis  
While authors [14, 26, 27, 49, 50] have conceptualised this liminal state as the new normal, it could be 
argued that labelling it as normality obscures young women’s perception of their current state as 
temporary. For example, one study explores how women adapt to a new normal by rebuilding their 
identity through breast reconstruction [27]. However, for a young woman unsure of her menopausal 
and fertility status, being able to rebuild her identity on any solid ground is precluded by the 
temporary nature of her situation. The ambivalence which women expressed in their interviews 
illustrated that, while there were positive outcomes of breast cancer and their lives had, in many ways, 
resumed previous routines and structure, the sense that their current state was only temporary was 
ever-present, and uncertainty and liminality permeated their everyday lives. 
Discussion 
The accounts of the young women above suggest that the end of initial treatment was accompanied by 
a sense of unease and uncertainty in relation to recurrence and survival, and fertility and menopausal 
status. These experiences resulted in a liminal state (Little et al. 1998). The young women found this 
experience of profound uncertainty at the end of initial treatment to be in contrast to their own and 
others’ expectations of life after cancer. It has been argued elsewhere that there is an emphasis on a 
return to ‘normal’ after cancer treatment (Little et al. 1998), but that this does not reflect the reality. 
The women in this study found themselves feeling distant from others because they could not 
communicate the uncertainty engendered by living with a history of cancer. This can be understood as 
‘communicative alienation’ which Little et al. identified as a facet of liminality.  
As in Little et al.’s formulation of liminality, the young women experienced a sense of being bound 
by time in ways which they had not been before. The young women’s perceptions about the future 
were altered, and their fears about recurrence were magnified by the possibility of so many decades 
ahead during which breast cancer could recur. The constraints of treatment timescales meant that, 
after initial treatment, young women with a history of breast cancer experienced a loss of control or 
agency over their life course, as their futures would be determined by the recommendations of health 
professionals, and whether or not they experienced a recurrence while on Tamoxifen. The 
implications for the young women’s life course, in terms of whether they would be able to have 
children, would not become clear for several years after initial treatment. Even the women who were 
told that their fertility was normal remained unconvinced and uncertain.  
Regardless of future family plans, the uncertain menopausal state which treatment induced for many 
of the young women was experienced as a liminal state because of the inability of health professionals 
to define their menopause as permanent or temporary. As a result, they found themselves situated 
“betwixt and between” fixed identities (Hockey and James 2003:24): neither clearly post- nor pre-
menopausal. Most of the young women would have to live with an unknown fertility, and an 
unknown menopausal status, for many years after initial treatment. While previous research (Trusson 
2013) has identified liminality in the accounts of women with a history of breast cancer, this 
dimension is related to the young’s women’s life stage at diagnosis, and it therefore extends 
understanding of life after breast cancer. This dimension of uncertainty is central to understanding 
young women’s experiences after breast cancer. Previous researchers have identified the significance 
of uncertainty regarding fertility for women living beyond cancer, and called for further research into 
this issue (Halliday and Boughton 2011; Halliday et al. 2014; Perz et al. 2014). This paper has aimed 
to increase understanding of uncertainty after breast cancer. It has also emphasised the importance of 
timing and time in understanding the experience of living beyond breast cancer. 
Strengths and limitations of the research 
The decision to use semi-structured interviews enabled a shared control over the interview, to some 
extent, and also the flexibility to explore emergent issues. Data from interviews should be seen as a 
product of a given social interaction, rather than a straightforward, objective account of ‘the truth’ 
[51]. However, the aim of the study was to explore the young women’s own perspectives on their 
experience, and, therefore, interviews enabled this. Little et al. (1998) argued that liminality after 
cancer was an enduring state, one which may continue until the end of a person’s life, whether from 
cancer or another reason. Further research could explore this in the accounts of young women living 
ten or more years beyond breast cancer. 
Conclusions 
These findings contribute to a nuanced understanding of the impact on young women’s life course 
after breast cancer, identifying ongoing uncertainty as central, and identifying age-related dimensions 
of liminality. The young women’s horizons had shifted in the same way that they might for older 
women, but the long-term consequences for their life course would not become clear for many years 
after diagnosis, and uncertainty about survivorship, and their futures, permeated their everyday lives. 
Reproduction and fertility have been identified in previous studies as among the most important 
concerns of younger women living with a history of breast cancer [20, 44, 46], but here I highlight the 
importance of the uncertainty about fertility and the way that this can be understood as a liminal state 
for the young women. 
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